Efficacy of BAFF in Monitoring Treatment Response in Early Vietnamese Systemic Sclerosis Patients
DOI:
https://doi.org/10.3889/oamjms.2019.070Keywords:
BAFF, Systemic SclerosisAbstract
BACKGROUND: B-cell activating factor (BAFF) is considered to have a role in the pathogenesis of systemic sclerosis (SSc).
AIM: We conducted a longitudinal study on early SSc patients to determine the change in BAFF serum level after treatment and its association with organ involvements.
METHODS: A total of 46 patients (32 diffuse, 14 limited) were recruited, among which 35 patients (24 diffuse, 11 limited) completed 12-month follow-up.
RESULTS: Higher pretreatment BAFF levels were observed in patients with positive anti-topoisomerase antibody (ATA) (2252.1 ± 899.7 pg/ml versus 1475.5 ± 697.6 pg/ml in ATA-negative patients; p = 0.01) and muscular involvement (2741.9 ± 1039.9 pg/ml versus 1897.2 ± 762.9 pg/ml in patients without muscular involvement; p = 0.005). Lower levels were observed in patients with interstitial lung disease (ILD) (1926.7 ± 757.9 pg/ml versus 2721.6 ± 1131.4 pg/ml in non-ILD patients; p = 0.01). After treatment, BAFF level reduced significantly in diffuse SSc patients (1652.2 ± 892.7 pg/ml versus 2147.6 ± 945.5 pg/ml before treatment; p = 0.03).
CONCLUSION: Patients with worsening outcome had the highest pretreatment BAFF level and was associated with increased BAFF level after treatment. BAFF can be used to predict and monitor patients’ response to therapy.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Yoshizaki A. B lymphocytes in systemic sclerosis: Abnormalities and therapeutic targets. The Journal of Dermatology. 2016; 43(1):39-45. https://doi.org/10.1111/1346-8138.13184 PMid:26782005
Yoshizaki A, Iwata Y, Komura K, Ogawa F, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Tedder TF. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. The American journal of pathology. 2008; 172(6):1650-63. https://doi.org/10.2353/ajpath.2008.071049 PMid:18467694 PMCid:PMC2408424
François A, Chatelus E, Wachsmann D, Sibilia J, Bahram S, Alsaleh G, Gottenberg JE. B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis research & therapy. 2013; 15(5):R168. https://doi.org/10.1186/ar4352 PMid:24289101 PMCid:PMC3978899
Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. The Lancet. 2011; 377(9767):721-31. https://doi.org/10.1016/S0140-6736(10)61354-2
Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2006; 54(1):192-201. https://doi.org/10.1002/art.21526 PMid:16385515
Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, . . . group, ERs. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015; 74(6):1188-1194. https://doi.org/10.1136/annrheumdis-2013-204522 PMid:24442885
Hudson M, Fritzler MJ. Diagnostic criteria of systemic sclerosis. Journal of autoimmunity. 2014; 48:38-41. https://doi.org/10.1016/j.jaut.2013.11.004 PMid:24461384
Kowal-Bielecka O, Landewé R, Avouac J, Chwiesko S, Miniati I, Czirjak L, Clements P, Denton C, Farge D, Fligelstone K, Földvari I. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Annals of the rheumatic diseases. 2009; 68(5):620-8. https://doi.org/10.1136/ard.2008.096677 PMid:19147617
Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Müller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Annals of the rheumatic diseases. 2007; 66(6):754-63. https://doi.org/10.1136/ard.2006.062901 PMid:17234652 PMCid:PMC1954657
Becker-Merok A, Nikolaisen C, Nossent HC. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus. 2006; 15(9):570-6. https://doi.org/10.1177/0961203306071871 PMid:17080911
Matsushita T, Fujimoto M, Hasegawa M, Tanaka C, Kumada S, Ogawa F, Takehara K, Sato S. Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF. The Journal of rheumatology. 2007; 34(10):2056-62. PMid:17896803
Forestier A, Guerrier T, Jouvray M, Giovannelli J, Lefèvre G, Sobanski V, Hauspie C, Hachulla E, Hatron PY, Zéphir H, Vermersch P. Altered B lymphocyte homeostasis and functions in systemic sclerosis. Autoimmunity reviews. 2018; 17(3):244-55. https://doi.org/10.1016/j.autrev.2017.10.015 PMid:29343447
López-Cacho JM, Gallardo S, Posada M, Aguerri M, Calzada D, Mayayo T, . . . Cárdaba B. Association of Immunological Cell Profiles with Specific Clinical Phenotypes of Scleroderma Disease. BioMed Research International. 2014; 1-8. https://doi.org/10.1155/2014/148293 PMid:24818126 PMCid:PMC4004116
Matsushita T, Kobayashi T, Mizumaki K, Kano M, Sawada T, Tennichi M, Okamura A, Hamaguchi Y, Iwakura Y, Hasegawa M, Fujimoto M. BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance. Science advances. 2018; 4(7):eaas9944.
Yoshizaki A, Sato S. Abnormal B lymphocyte activation and function in systemic sclerosis. Annals of dermatology. 2015; 27(1):1-9. https://doi.org/10.5021/ad.2015.27.1.1 PMid:25673924 PMCid:PMC4323585
Mavropoulos A, Simopoulou T, Varna A, Liaskos C, Katsiari CG, Bogdanos DP, Sakkas LI. Breg cells are numerically decreased and functionally impaired in patients with systemic sclerosis. Arthritis & Rheumatology. 2016; 68(2):494-504. https://doi.org/10.1002/art.39437 PMid:26414243
Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2004; 50(6):1918-27. https://doi.org/10.1002/art.20274 PMid:15188368
François A, Gombault A, Villeret B, Alsaleh G, Fanny M, Gasse P, Adam SM, Crestani B, Sibilia J, Schneider P, Bahram S. B cell activating factor is central to bleomycin-and IL-17-mediated experimental pulmonary fibrosis. Journal of autoimmunity. 2015; 56:1-1. https://doi.org/10.1016/j.jaut.2014.08.003 PMid:25441030
Needleman BW, Wigley FM, Stair RW. Interleukinâ€1, interleukinâ€2, interleukinâ€4, interleukinâ€6, tumor necrosis factor α, and interferonâ€Î³ levels in sera from patients with scleroderma. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 1992; 35(1):67-72. https://doi.org/10.1002/art.1780350111
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Vu Nguyen Minh, Khang Tran Hau, Matushita Takashi, Vinh Nguyen Ha, Long Hoang Bao, My Le Huyen, Doanh Le Huu, Thuong Nguyen Van, Marco Gandolfi, Francesca Satolli, Claudio Feliciani, Michael Tirant, Aleksandra Vojvodic, Torello Lotti
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All rights reserved.
